title: Ezogabine (retigabine).
abstract: Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the U.S. Food and Drug Administration (F.D.A.) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).
authors.affiliation: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA. stafstrom@neurology.wisc.edu
authors.forename: Carl E
authors.initials: CE
authors.lastname: Stafstrom
authors.forename: Seden
authors.initials: S
authors.lastname: Grippon
authors.forename: Peter
authors.initials: P
authors.lastname: Kirkpatrick
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002219:Carbamates / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004828:Epilepsies, Partial / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D010655:Phenylenediamines / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; C101866:ezogabine